EcoDrugPlus

Maltase-Glucoamylase 2 (Putative)

Ensembl ID : ENSUPAG00010007084
Gene Symbol: MGAM2
1 Cross references
390 Possible Orthologues:

Matrix Metallopeptidase 1

Ensembl ID : ENSUPAG00010019633
Gene Symbol: MMP1
1 Cross references
352 Possible Orthologues:

Matrix Metallopeptidase 12

Ensembl ID : ENSUPAG00010019655
Gene Symbol: MMP12
3 Cross references
550 Possible Orthologues:

Matrix Metallopeptidase 13

Ensembl ID : ENSUPAG00010019662
Gene Symbol: MMP13
1 Cross references
200 Possible Orthologues:

Matrix Metallopeptidase 14

Ensembl ID : ENSUPAG00010011304
Gene Symbol: MMP14
1 Cross references
269 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSUPAG00010014403
Gene Symbol: MMP2
3 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 3

Ensembl ID : ENSUPAG00010019608
Gene Symbol: MMP3
3 Cross references
493 Possible Orthologues:

Matrix Metallopeptidase 7

Ensembl ID : ENSUPAG00010019569
Gene Symbol: MMP7
3 Cross references
163 Possible Orthologues:

Matrix Metallopeptidase 8

Ensembl ID : ENSUPAG00010019593
Gene Symbol: MMP8
3 Cross references
111 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSUPAG00010002334
Gene Symbol: MMP9
3 Cross references
214 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSUPAG00010003456
Gene Symbol: MTOR
3 Cross references
214 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSUPAG00010005175
Gene Symbol: MC3R
3 Cross references
138 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).